GATA4 is a survival factor in adult cardiac myocytes but is not required for α1A-adrenergic receptor survival signaling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 2, 2008, Pages

  Huang, Yuan ^a   Wright, Casey D ^a   Kobayashi, Satoru ^a   Healy, Chastity L ^a   Elgethun, Megan ^a   Cypher, Andrew ^a   Liang, Qiangrong ^a   O'Connell, Timothy D ^a  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

Author keywords

Alpha 1 adrenergic receptors; Extracellular signal regulated kinase; Norepinephrine

Indexed keywords

ALPHA 1A ADRENERGIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; NORADRENALIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR GATA 4; ADRENERGIC RECEPTOR ALPHA(1A); ADRENERGIC RECEPTOR ALPHA(1B); ALPHA 1 ADRENERGIC RECEPTOR; GATA4 PROTEIN, MOUSE; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; DNA BINDING; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; HEART STRESS; KNOCKOUT MOUSE; MALE; MORTALITY; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; AGE; ANIMAL; APOPTOSIS; CELL CULTURE; CELL MEMBRANE; CONGESTIVE CARDIOMYOPATHY; DISEASE MODEL; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

AGE FACTORS; ANIMALS; APOPTOSIS; CARDIOMYOPATHY, DILATED; CELL MEMBRANE; CELL SURVIVAL; CELLS, CULTURED; CYTOPROTECTION; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GATA4 TRANSCRIPTION FACTOR; HUMANS; MALE; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; NOREPINEPHRINE; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, ALPHA-1; RECOMBINANT FUSION PROTEINS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 52449091866     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.01204.2007     Document Type: Article

References (26)

1. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: the antihypertensive, and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283: 1967-1975, 2000.
2. Aries A, Paradis P, Lefebvre C, Schwartz RJ, Nemer M. Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc Natl Acad Sci USA 101: 6975-6980, 2004.
3. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 51: 651-690, 1999.
4. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molk- entin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19: 6341-6350, 2000.
5. Chalothorn D, McCune DF, Edelmann SE, Garcia-Cazarin ML, Tsujimoto G, Piascik MT. Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol 61: 1008-1016, 2002.
6. Charron F, Tsimiklis G, Arcand M, Robitaille L, Liang Q, Molkentin JD, Meloche S, Nemer M. Tissue-specific GATA factors are transcriptional effectors of the small GTPase RhoA. Genes Dev 15: 2702-2719, 2001.
7. Cohn JN. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies Introduction. Circulation 87: VI1-VI4, 1993.
8. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984.
9. Communal C, Singh K, Pimentel DR, Colucci WS. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway. Circulation 98: 1329-1334, 1998.
10. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, O'Connell TD. An α1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation 115: 763-772, 2007.
11. Kobayashi S, Lackey T, Huang Y, Bisping E, Pu WT, Boxer LM, Liang Q. Transcription factor GATA4 regulates cardiac BCL2 gene expression in vitro and in vivo. FASEB J 20: 800-802, 2006.
12. Liang Q, De Windt LJ, Witt SA, Kimball TR, Markham BE, Molkentin JD. The transcription factors GATA4 and GATA6 regulate cardiomyocyte hypertrophy in vitro and in vivo. J Biol Chem 276: 30245-30253, 2001.
13. Liang Q, Wiese RJ, Bueno OF, Dai YS, Markham BE, Molkentin JD. The transcription factor GATA4 is activated by extracellular signal-regulated kinase 1- and 2-mediated phosphorylation of serine 105 in cardiomyocytes. Mol Cell Biol 21: 7460-7469, 2001.
14. 1A-adrenergic receptor overexpression induces enhanced cardiac contractility but not hypertrophy. Circ Res 89: 343-350, 2001.
15. Morimoto T, Hasegawa K, Kaburagi S, Kakita T, Wada H, Yanazume T, Sasayama S. Phosphorylation of GATA-4 is involved in alpha 1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 275: 13721-13726, 2000.
16. Morris DP, Price RR, Smith MP, Lei B, Schwinn DA. Cellular trafficking of human α1a-adrenergic receptors is continuous and primarily agonist-independent. Mol Pharmacol 66: 843-854, 2004.
17. O'Connell TD, Ishizaka S, Nakamura A, Swigart PM, Rodrigo MC, Simpson GL, Cotecchia S, Rokosh DG, Grossman W, Foster E, Simpson PC. The α(1A/C)- and α(1B)-adrenergic receptors are required for physiological cardiac hypertrophy in the double-knockout mouse. J Clin Invest 111: 1783-1791, 2003.
18. O'Connell TD, Rodrigo MC, Simpson PC. Isolation and culture of adult mouse cardiac myocytes. Methods Mol Biol 357: 271-296, 2007.
19. O'Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker AJ, Foster E, Grossman W, Simpson PC. α-1-Adrenergic receptors prevent a maladaptive cardiac response to pressure overload. J Clin Invest 116: 1005-1015, 2006.
20. Pediani JD, Colston JF, Caldwell D, Milligan G, Daly CJ, McGrath JC. Beta-arrestin-dependent spontaneous alpha1a-adrenoceptor endocytosis causes intracellular transportation of alpha-blockers via recycling compartments. Mol Pharmacol 67: 992-1004, 2005.
21. Pu WT, Ma Q, Izumo S. NFAT transcription factors are critical survival factors that inhibit cardiomyocyte apoptosis during phenylephrine stimulation in vitro. Circ Res 92: 725-731, 2003.
22. 1-adrenergic receptor interaction: evidence for independent regulation of growth and beating. Circ Res 56: 884-894, 1985.
23. Stanasila L, Perez JB, Vogel H, Cotecchia S. Oligomerization of the α1a- and α1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J Biol Chem 278: 40239-40251, 2003.
24. Valks DM, Cook SA, Pham FH, Morrison PR, Clerk A, Sugden PH. Phenylephrine promotes phosphorylation of Bad in cardiac myocytes through the extracellular signal-regulated kinases 1/2 and protein kinase A. J Mol Cell Cardiol 34: 749-763, 2002.
25. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87: 619-628, 1996.
26. 2+/calmodulin kinase II. J Clin Invest 111: 617-625, 2003.